Navigation Links
Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
Date:12/7/2010

ent," said Dale Ando, M.D, Sangamo's vice president of therapeutic development and chief medical officer. "Using a mouse model of hemophilia B, we have demonstrated successful functional correction of a human gene for the clotting factor, Factor IX, by direct systemic delivery into the animal rather than by delivery into cells ex vivo. Our ZFN approach, which enables permanent correction of the disease-related gene in situ, circumvents the problems of traditional gene-addition approaches that result in random insertion and the loss of normal regulation of the gene which may lead to malignancy or other unintended consequences."

Scientists demonstrated efficient ZFN-mediated correction of a defective human Factor IX gene in a mouse model of hemophilia B by delivering ZFNs and a corrected donor DNA sequence directly into the animals.  Stable levels of protein made from the corrected human gene could be measured in the plasma of the treated animals and resulted in the restoration of normal rates of blood clotting for the period of the study.  The study was carried out in the laboratory of Katherine High, M.D., Investigator, Howard Hughes Medical Institute, Professor of Pediatrics, University of Pennsylvania School of Medicine and Director, Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia, in collaboration with Sangamo scientists.

"These data represent a fundamental step forward and provide important proof of concept that ZFNs can be delivered efficiently in vivo and have potential therapeutic value for the treatment of human disease," stated Edward Lanphier, Sangamo's president and chief executive officer. "Our ZFN technology platform is broadly applicable and has been demonstrated to enable permanent gene modification, as in our CCR5 HIV clinical programs and in the studies presented this week at ASH.  We believe that this technology, which can be applied to any disease-relevant
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
2. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
3. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
4. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
5. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
6. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
7. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
8. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
9. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Edison Investment Research, ... the initiation of full coverage of BioAlliance ... and marketing products for orphan oncology and ... (Logo: http://photos.prnewswire.com/prnh/20130417/608168) Edison has today ... merits of BioAlliance Pharma, focusing in particular ...
(Date:6/18/2013)... Toronto, Canada (PRWEB) June 18, 2013 ... FDA oversight of pharmaceutical advertising and promotion, and ... , Viewers will learn how to apply these ... enforcement examples:, ,     The fundamentals on ... advertising and promotional labeling ,     Assessing traditional ...
(Date:6/18/2013)... , June 18, 2013 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/cmbgcv/north_american ) has announced the ... Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market ... Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] ... 2017" report to their offering. ...
(Date:6/18/2013)... June 18, 2013 Earlier this year, Google ... platform. As this directly impacts the core component of ... one of the most sweeping updates since its inception in ... Technologies recently posted a very informative article on ... ‘must-have’ upgrade date for enhanced campaigns . Only ...
Breaking Biology Technology:Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 3Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 2Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure 3
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), ... today announced that it has received clearance ... to begin marketing additional,diameters of its Quill(TM) ... The Quill(TM) SRS PDO is a longer-lasting ...
... fraught with,flare-ups of pain, or breakthrough pain, may ... new easy-to-use oral drug delivery system developed by,BioDelivery ... Cancer patients frequently experience two types of pain: ... continuous pain,present for long periods of time, and ...
... the Fourth ... Quarter, FRAZER, ... a 12-week, Phase 3 clinical,trial of FENTORA(R) (fentanyl buccal tablet) [C-II] in ... The study achieved statistical significance on the primary,endpoint. Results across the 12 ...
Cached Biology Technology:Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 2Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 3Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 4Novel Technology Breaks Through Cancer Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 4Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 5
(Date:6/18/2013)... Research Council, Laboratory of Molecular Biology, has been ... Young Investigator Award. Torrent is being recognized for ... algorithm to predict antimicrobial regions in proteins. Luis ... now applying this algorithm to interrogate full genomes ... with very appealing results." , Torrent obtained ...
(Date:6/18/2013)... The herbal extract of a yellow-flowered mountain plant long ... lifespan of fruit fly populations by an average of ... it,s how Rhodiola rosea , also ... attention of study leaders Mahtab Jafari and Sam Schriner. ... manner completely unrelated to dietary restriction and affects different ...
(Date:6/18/2013)... shows that weight gain and increased head size in the first ... at early school age. , The study was led by University ... 13,800 children who were born full-term. , The results, published in ... put on 40% of their birthweight in the first four weeks ... six years of age, compared with babies who only put on ...
Breaking Biology News(10 mins):The American Society for Microbiology honors Marc Torrent 2Herbal extract boosts fruit fly lifespan by nearly 25 percent, UCI study finds 2IQ link to baby's weight gain in first month 2
... announce 7.5 million of funding for a series of projects ... H1N1 2009 or ,swine flu,. The research will look ... pig and human populations, and in hospital intensive care units. ... reported in Mexico in March this year. In June, as ...
... researchers from Carnegie Mellon University, Goettingen Medical School in ... Kingdom have received a Human Frontiers Science Program (HFSP) ... better understand the "cellular GPS" system that guides neurons ... In the course of the development and repair of ...
... CORVALLIS, Ore. - Penguins that died 44,000 years ago ... challenge the accuracy of traditional genetic aging measurements, and ... of many specimens by 200 to 600 percent. ... DNA testing to be 100,000 years old may actually ...
Cached Biology News:£7.5 million ($12.6 million) collaborations lead UK research community's response to H1N1 pandemic 2£7.5 million ($12.6 million) collaborations lead UK research community's response to H1N1 pandemic 3£7.5 million ($12.6 million) collaborations lead UK research community's response to H1N1 pandemic 4Carnegie Mellon researchers to develop probes to study cellular GPS 2Ancient penguin DNA raises doubts about accuracy of genetic dating techniques 2
... with a modular approach to instrument control, ... Plus NDS family provides modular software components ... management, giving you the flexibility to choose ... now and that can grow as your ...
... Workgroup solution is a highly scalable ... expression data in a workgroup or ... in over 40 leading pharmaceutical, biotechnology, ... GeneSpring Workgroup streamlines genomics research at ...
... designed for proteomic scale kinase profiling, ... and drug discovery research built on ... on-chip synthesis platform. These microarrays are ... Protein Kinase Substrate - Peptide Microarray ...
... 18 amino acid synthetic peptide whose sequences are derived from mouse ... carboxy terminus): S(21) - S - M - P - L ... A - I - D - K - K - I ... peptide may be used for neutralization and control experiments with the ...
Biology Products: